Biohaven Ltd. (NYSE:BHVN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Posted by Brian Himes on Jul 30th, 2026

Shares of Biohaven Ltd. (NYSE:BHVN – Get Free Report) have been given an average rating of “Moderate Buy” by the eighteen ratings firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, ten have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $21.6250.

A number of research analysts have issued reports on BHVN shares. Needham & Company LLC set a $11.00 target price on shares of Biohaven in a report on Monday, June 29th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Biohaven in a research report on Wednesday, May 27th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Biohaven in a research report on Friday, June 26th. Bank of America reiterated an “underperform” rating and issued a $11.00 price objective (down from $12.00) on shares of Biohaven in a report on Monday, June 29th. Finally, Citigroup lifted their price objective on Biohaven from $14.00 to $17.00 and gave the stock a “buy” rating in a report on Thursday, April 2nd.

Get Our Latest Stock Analysis on Biohaven

Biohaven Trading Down 2.6%

BHVN opened at $13.42 on Friday. The business has a fifty day moving average price of $13.43 and a 200 day moving average price of $11.53. The company has a debt-to-equity ratio of 1.87, a current ratio of 7.41 and a quick ratio of 7.41. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of -2.37 and a beta of 1.28. Biohaven has a 12 month low of $7.48 and a 12 month high of $18.57.

Biohaven (NYSE:BHVN – Get Free Report) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Sell-side analysts expect that Biohaven will post -3.1 earnings per share for the current fiscal year.

Institutional Trading of Biohaven

Large investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. lifted its position in Biohaven by 113.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock worth $36,000 after buying an additional 1,268 shares in the last quarter. IFP Advisors Inc boosted its holdings in Biohaven by 55.4% in the fourth quarter. IFP Advisors Inc now owns 4,069 shares of the company’s stock valued at $46,000 after acquiring an additional 1,450 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in Biohaven by 178.4% during the fourth quarter. EverSource Wealth Advisors LLC now owns 4,031 shares of the company’s stock worth $46,000 after acquiring an additional 2,583 shares in the last quarter. Arax Advisory Partners lifted its position in Biohaven by 943.3% in the 4th quarter. Arax Advisory Partners now owns 4,914 shares of the company’s stock valued at $55,000 after acquiring an additional 4,443 shares in the last quarter. Finally, Essential Partners LLC increased its position in shares of Biohaven by 31.7% during the first quarter. Essential Partners LLC now owns 9,020 shares of the company’s stock valued at $76,000 after acquiring an additional 2,169 shares during the last quarter. 88.78% of the stock is owned by institutional investors.

About Biohaven

(Get Free Report)

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.